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ABSTRACT
As part of the search for the Huntington disease (HD)
gene we have cloned and sequenced 34 kb of genomic
DNA containing the full-length gene for the /3-subunit
of the human cGMP phosphodiesterase (/3-cGMP PDE).
This gene is localized to 4p16.3 about 700 kb proximal
to the 4p telomere and represents the most telomeric
gene characterized on 4p to date. We show that this
gene is comprised of 22 exons spanning approximately
43 kb of genomic DNA. We also provide 400 bp
immediately 5' to the putative initiator methionine and
700 bp of 3' flanking sequences. Northern blot analysis
of several human tissues revealed a highly abundant
3.5 kb transcript and a minor signal of 4.5 kb in retinal
tissue. Alignment of the deduced amino acid sequence
to the previously identified /3-subunits of the cGMP
PDEs of mouse and cow demonstrates highly
significant similarities and, therefore, confirms the
identity of the cloned gene. A defect in the /3-subunit
of the cGMP PDE gene has been shown recently to be
the cause for the retinal degeneration in the rd mouse.
The cloning of the human homolog and the knowledge
of its genomic organization with exon/intron
boundaries will allow rapid assessment of the role of
this gene in the causation of human retinopathies.
INTRODUCTION
Approaches to cloning genes for specific diseases with unknown
biochemical defects have concentrated on the identification of
minimal candidate regions likely to contain the defective gene.
With this strategy, the gene is cloned based on its chromosomal
location rather than its functional properties. Alternatively, the
candidate gene approach bases the identification of a disease gene
on a theoretical hypothesis as to the pathogenesis of the disorder.
In the future, we are increasingly likely to see the cloning of
particular disease genes by a combination of the candidate gene
approach in conjunction with the knowledge of the location of
the mutant gene to a particular chromosomal region.
We have previously reported on the cloning and physical
characterization of a candidate region for the Huntington disease
(HD) gene within chromosomal region 4pl6.3 (1). A total of
15 CpG-rich islands were characterized and sequences
surrounding these islands were tested for cross species
conservation. This strategy allowed the rapid identification of
putative coding sequences within the cloned region. As part of
the search for the HD gene, we now report the cloning and
characterization of a gene from this candidate region. GeneBank
alignment established significant similarities to previously cloned
genes from mouse and cow and identifies the isolated gene as
the 0-subunit of the cyclic GMP phosphodiesterase (cGMP PDE).
In retinal rod cells, cGMP PDE is involved in the
phototransduction pathway and consists of two large catalytic
subunits, a and /3, and two small inhibitory y polypeptides (2,3).
The genes encoding the a-subunit of cGMP PDE of human (4),
cow (3,5) and mouse (6), the /3-subunit of cow (7) and mouse
(8) and the 7-subunit of human (9), cow (10) and mouse (11)
have previously been cloned and assigned to human or mouse
chromosomes. The a-subunit was mapped to 5q31.2-5q34 in
humans (4) and to chromosome 18 in mouse (12), and the /?-
subunit was localized in mouse to chromosome 5 (8, 13) and
the 7-subunit to mouse chromosome 11 (14).
In rod cells the signalling cascade begins with the absorption
of a photon by rhodopsin which is localized in the rod outer
segment membranes. The photon excitement triggers a
conformational change in the receptor protein which binds a
membrane-associated G protein, transducin. This catalyzes a
GDP-GTP exchange reaction on the a-subunit of transducin and
the dissociation from the @/y subunit complex. The GTP bound
a-subunit of transducin then activates a photoreceptor-specific
phosphodiesterase (PDE) complex which hydrolyzes 3', 5'-cyclic
GMP to 5' GMP. As cGMP acts allosterically on the sodium
channels of the plasma membrane a reduction of intracellular
concentrations of cGMP leads to the closure of the channels,
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consequently to hyperpolarization of the plasma membrane and,
thereby, visual signaling (15,16).
Mutations in any one of the many genes involved in the
complex biochemistry of the eye could theoretically impair vision.
Until recently the biochemical defects underlying retinal diseases
were mostly unknown. However, the application of DNA
technology to these problems has led to new insights. A few forms
of human hereditary retinal degeneration such as gyrate atrophy
of the choroid and retina (17), choroideraemia (18), and
autosomal dominant retinitis pigmentosa (19) have been linked
to mutations in specific genes and it has recently been
demonstrated that the gene encoding the j3-subunit of the rod
cGMP PDE is responsible for the autosomal recessive retinal
degeneration in the rd mouse (8). The isolation of the human
homolog to the mouse j3-subunit of the cGMP PDE will now
allow rapid determination as to whether any human retinal disease
is caused by a defect in this gene. Moreover, the knowledge of
the exon/intron sequences of this gene will rapidly facilitate the
assessment of possible mutations without the need for obtaining
retinal RNA from affected persons.
MATERIALS AND METHODS
Isolation of overlapping cosmid clones and sequence analysis
Overlapping cosmids cl6Dp, cl7QBl, and cl8E were isolated
as part of a cosmid walking project with the goal of cloning a
candidate region containing the HD gene. A detailed description
of the cosmid libraries, construction, screening procedures,
determination of overlapping fragments and restriction mapping
has been described elsewhere (1). Sequence analysis of purified
plasmid subclones (vector: Bluescript KS n( + ),Stratagene) was
done using the dideoxy nucleotide chain termination method (20)
and the Sequenase DNA sequencing kit (US Biochemicals).
Alu element-mediated PCR cloning
Alu primer A IS (TCATGTCGACGCGAGACTCCATCTC-
AAA) was used in an Alu element-mediated PCR reaction as
described previously (21) in order to synthesize and subclone
small fragments from cosmid cl6Dp.
Identification of intron/exon junctions and sequence data
analysis
Tentative splice junctions were first determined by alignment of
the genomic sequence with the bovine /3-subunit cDNA sequence
in the GenBank database (acc.no JO 5553). Splice consensus
sequences were then scored by calculating the 'discrimination
energy' (22, 23). Nucleotide sequence data from the bovine and
mouse (acc.no X55968) /3-subunit and from the bovine (acc.no.
M 26043) and human (acc.no. M26061) a-subunit cGMP PDEs
have been extracted from GenBank Version 67. The translated
peptide sequences were then aligned using Hein's program (24).
Localisation of the /3-subunit cGMP PDE locus by pulsed field
gel electrophoresis analysis
The preparation of high molecular weight DNA and the
separation of large restriction fragments using the transverse
alternating field electrophoresis system (Beckman Inc.) were
performed as described previously (1).
RNA preparation, Northern blot analysis
RNAs from various tissues were isolated using a single step
method by homogenization in guanidinium isothiocyanate as
described (25). Poly(A)+ RNA was purified using oligo(dT) push
columns (Stratagene). RNA samples were size fractionated on
a 2.2M formaldehyde/1 % agarose gel and transferred to Hybond
N membranes. Hybridizations were done at 65°C in 0.5M
sodium phosphate buffer pH 7.2/7% sodium dodecyl sulfate (26)
RESULTS
Cloning and structure of the /3-subunit of the cGMP-PDE
gene
We recently reported the isolation of 460 kb of contiguously
overlapping genomic DNA from a candidate region for the HD
gene (1). In order to rapidly define exonic sequences within the
contig DNA we choose an approach which included the
characterization of CpG-rich islands and the subsequent testing
of adjacent sequences for cross-species conservation.
Probe Kl, a single copy 1.1 kb subclone of cosmid cl6Dp
(fig 1) which was generated by using Alu element-mediated PCR
showed cross species conservation in several mammalian species
(data not shown). Clone Kl was sequenced and searched in the
GenBank database for sequence similarities with previously
described genes. Computer alignment revealed significant
similarities between 138 nucleotides (nt) of subclone Kl and the
/3-subunits of the cyclic GMP phosphodiesterase from cow
(124/138 nt identical) and mouse (123/138 nt identical).
In order to determine the complete genomic locus of this gene,
we initiated the sequencing of genomic fragments between CpG-
rich islands I and II (fig 1). As the Kl fragment is flanked by
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Figure 1. Physical map and genomic organization of exons 1 to 22 of the human /3-subunit of the cGMP PDE. The upper panel shows three overlapping cosmids
cl6Dp, C17QB1, and cl8E together encompassing the j3-subunit cGMP PDE locus. The horizontal bars below depict subclones used in the sequencing analysis
or in Southern and Northern blot experiments. The CpG-rich islands I and II have been previously defined (1). Solid boxes represent exons 1 to 22. 5' and 3' flanking
regions are shown as open boxes. EcoRI fragments and corresponding sizes in kb are shown below. The 5'-3' orientation of the /3-cGMP PDE locus within 4p is indicated.
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these two islands within a distance of approximately 30 kb of
genomic DNA (fig 1) and the mouse j3-subunit of the cGMP PDE
detects a transcript of approximately 3.1 kb (8) we reasoned that
the complete gene could well be contained within the 30 kb of
genomic DNA.
EcoRl fragments from cosmids cl6 Dp and cl7 QB1 were
further digested with different enzymes in order to obtain
overlapping fragments in a convenient size range for sequence
analysis (fig 1). Alignment of the obtained sequences with the
cDNAs of the bovine (7) and mouse (8) /3-subunits of the cGMP
PDEs revealed that 19 exons including the 3' flanking region
were contained within the 30 kb of genomic DNA (fig 1).
However, nucleotides 1 to 712 as numbered from the initiation
codon (ATG, A=l ) of the bovine cDNA were not contained
within the sequenced genomic fragments.
In order to identify the missing 5' exons we synthesized primer
pdel corresponding to nt 675 —700 of the bovine /3-subunit cGMP
PDE cDNA and hybridized this oligomer to the EcoRI digested
fragments from overlapping cosmids cl6Dp, cl7QBl, and cl8E.
Pdel hybridized specifically to a 4 kb EcoRI fragment in cosmid
cl8E at least 16 kb distal to the last identified exon and
approximately 8 kb distal to CpG-rich island II (fig 1). We
sequenced this exon (90 bp) and its intronic boundaries and
confirmed significant nucleotide similarities (over 82%) with the
bovine and mouse homologs. Subsequently, primers pde 3 (nt
567-588) and pde 6r (nt 425-446) identified the two most 5'
exons located in the 4 kb and the adjacent 9 kb EcoRI fragments,
respectively (figl). The complete coding sequence including 400
bp of 5' and 700 bp of 3' flanking sequences are given in fig
2. An inserted Alu repeat within the 3' flanking region and
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Figure 2. Nucleotide sequences of exons 1 to 22 of the jS-subunit of the cGMP PDE including 400 bp of 5' and 700 bp of 3' flanking region. Exon/intron boundaries
are marked by a vertical bar. The putative stop codon TGA is indicated by an asterisk. The nucleotide sequence is numbered from the transcription start codon
ATG based on the comparison to the bovine homolog position (translation initiation codon ATG with A= 1) (7). The deduced amino acid sequence is given in a
one letter code below. An inserted Alu repeat at the 3' flanking region and two possible polyadenylation signals are underlined.
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approximately 120 bp downstream the putative stop codon is
underlined (fig 2)
Table 1 summarizes the data for the exon/intron organization
of exons 1 to 22 of the /3-subunit of the human cGMP PDE.
Alignment of the genomic sequence to the bovine /3-subunit of
the cGMP PDE in the GenBank database (acc.no JO 5553)
allowed a first tentative assignment of donor and acceptor splice
junctions. The discrimination energy score of donor and acceptor
splice recognition sequences (22, 23) was then calculated defining
the most likely splice sites. This score is included in the table
to indicate the strength of consensus of our assigned splice
junctions with previously published sequences. This method
scores a 'perfect' consensus as zero, with worsening agreement
indicated by an increasing positive score. The maximum (worst)
score for acceptors is 42.5 and for donors is 30.1. A survey of
764 human acceptor/donor sites found that the average acceptor
score is 5.1 (standard deviation 2.4) and the average donor score
is 3.16 (standard deviation 1.81) (23). Note that the donor splice
junction for exon 20 contains a 'GC rather than the 'GT' that
is almost universal in donor splice recognition sequences. Despite
this anomaly, the sequence has a score of 5.68, well within the
range expected for true splice junctions, and suggesting that the
remainder of the consensus area somehow compensates for the
lack of a 'GT'.
Conservation of the human, mouse and bovine /3-subunits of
the cGMP PDE and comparison to the human and bovine
a-subunits
Alignment of the deduced peptides of the /3-subunit of the human
cGMP phosphodiesterase (fig 2) to the mouse (8) and bovine (7)
homologs and in addition to the human and bovine a-subunits
Table 1: Exon/intron organization lor the human beta subunrt ol the cGMP PDE gene
Acceptor Sequence
TCCTCTCTTGCGGCAG T
GCAATTCCTGTTTCAG G
GTGCCCCTCCCTCCAG G
ACCTCTTCTCTGCCAG G
GTCTTCTGCTTCTCAG G
TGCTCTCTGCCCACAG C
TCTGATGCTTTTTCAG A
GACACCGCTCCCGCAG G
CTGCCATCCCCTCCAG T
CTGTGTCTCTGTGTAG C
ACAATCCCTCCCACAG A
CTCTCGGCTCCCCCAG G
GGCCCTGTCTCTACAG A
ACCACCTGTGTAACAG T
GGCATAACCTCCGCAG A
TGTTCCCTGGGTTCAG G
CGGTTTGTGTCTGCAG G
CTTCCTGTGCCTCCAG G
CTGTTCCTCCCACCAG C
TCTCGACTCCCCTCAG G
CTGTCTTCTCTTGCAG T
Score*'
5.92
6.10
3.19
3.67
3.24
4.57
6.34
6.90
5.67
7.83
6.08
3.83
5.25
10.12
9.25
6.69
5.22
3.41
5.26
4.74
3.49
Exon
Ho.
1
2
3
4
5
6
7
6
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Size
(bp)
469
151
90
141
75
65
67
48
150
144
66
147
108
111
87
101
108
64
75
84
151
62
Donor
GAG
GAT
CAG
AAG
CGG
TCC
TTT
CAG
GAG
CTG
CTG
GAG
ATG
AAG
GAG
CAA
CAT
AAC
ATT
AAG
AAG
Sequence
GTGGGT
GTGAGT
GTACCA
GTGAGG
GTGAGT
GTAAGT
GTCAGT
GTATCT
GTAAGC
GTGCGG
GTAAGA
GTGGGA
GTACGT
GTAGGC
GTTGGT
GTGCGC
GTGACC
GTTAGA
GTGAGT
GCGAGT
GTCTCG
Score
2.83
3.18
5.78
1.10
1.41
5.76
5.12
5.14
1.79
4.27
2.54
3.89
3.61
3.04
5.67
5.00
3.25
4.20
4.02
5.68
6.69
Intron
(bp)
>1600
>800
>16000
80
650
1080
230
600
300
1300
1400
>1700
250
500
560
250
650
300
1200
1240
>1400
a) The acceptor and donor splice junctions have been scored as the discrimination
energy (22, 23). A perfect consensus match would have a score of zero, while
the worst score for acceptors would be 42.5 and for donors would be 30.1. All
splice junctions score within the 95% confidence interval for known splices, except
the acceptor of exon 15, which falls slightly outside of this range. The donor
splice junction of exon 20 contains a 'GC' rather than the usual 'GT'. In a recent
survey in GenBank Version 58, 17 such nonconforming sites have been described
(46).
(4) reveals significant sequence similarities (data not shown). The
primary amino acid sequence from the human /3-subunit is 92 %
and 91% identical to the mouse and bovine /3-subunits,
respectively, and 71% identical to the human a-subunit of the
cGMP PDE gene. The bovine and mouse /3-subunits have an
amino acid residue similarity of 93%. This significant cross
species conservation of the deduced amino acid sequences
demonstrates the identity of the cloned gene as the /3-subunit of
the cGMP PDE. These data also indicate a close phylogenetic
relationship of the a- and the j3-subunits of the cGMP PDEs.
Northern blot analysis
We analyzed the expression pattern of the /3-subunit gene of the
cGMP PDE in various adult human tissues including frontal
cortex, adrenal, lung, esophagus, skeletal muscle, kidney, liver,
and retina (fig 3a). Northern blot filters with total RNA of these
tissues were hybridized with probe Kl, containing exons 18 and
19 (fig 1, fig 3a). The retinal RNA shows a major hybridization
signal corresponding to a 3.5 kb transcript and a minor signal
at 4.5 kb. All other tissues show no hybridization signal. In
addition we hybridized the Kl probe to poly (A)+ RNA isolated
from frontal cortex, skeletal muscle, adrenal, and lung total RNA.
A normal exposure of the autorad does not reveal a hybridization
signal in one of these tissues (fig 3b). However, an extreme
overexposure detects a weak signal only in frontal cortex poly
(A)+ RNA approximately 500-800 bp smaller than the major
retinal transcript (data not shown).
Physical localisation of locus D4S228 containing the /3-cGMP
PDE gene
We have previously reported the localisation and orientation of
a 460 kb cosmid contig close to the 4p telomere (1). The gene
for the /3-subunit of the human cGMP PDE maps to the most
distal region of this contig. Fig 4 summarizes the physical
mapping data obtained from PFGE analysis with three probes
which allows the construction of a physical long range map of
approximately 720 kb and which extends to the 4p telomere.
Probes PI.2 (D4S228), a 1.5 kb single copy probe from the
region proximal to CpG-rich island II (fig 1), 281 (D4S133) (27)
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Figure 3. Northern blot analysis of 20 /jg each of total (A) and 2 ng each of
poly(A)+ (B) RNA from several human tissues. The retinal lane in (B) contains
5 nf> of total RNA. The sizes were estimated by comparing to a commercially
available RNA ladder (BRL).
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and D5 (D4S90) (28) hybridize to the same 800 kb NotI fragment
(fig 4). The three loci also share a common 900 kb partial MM
fragment. A partially methylated Mlul site, however, separates
loci D4S133 and D4S228 from D4S90. D4S133 is physically
closely linked to D4S228. Both loci detect a common 90 kb Nrul
fragment. A SacII site which is part of CpG-rich island I (fig
1) separates the two loci and places IMS 133 proximal to this CpG
island.
In summary, our PFGE data demonstrate physical linkage
between D4S228 and the flanking loci D4S133 and D4S90. Since
it is well established that D4S90 is located within 350 kb from
the 4p telomere (29, 30) we conclude that the gene for the /3-
subunit of the cGMP PDE is located approximately 650 to 700
kb proximal to the 4p telomere (arrow in fig 4) and represents
to date the most telomeric gene characterized on 4p.
DISCUSSION
As part of the search for the Huntington disease gene we have
cloned and sequenced the complete genomic locus containing the
gene encoding the /3-subunit of the human cGMP PDE. We
identified 22 exons including 5' and 3' flanking regions. In
addition, we determined the orientation and the precise
localisation of the gene approximately 700 kb from the 4p
telomere in 4pl6.3. The gene is predominantly expressed in retina
with a transcript size of about 3.5 kb. In addition, we also detected
expression with very low abundancy and an altered sized
transcript in brain.
The deduced peptide sequence of the identified gene has been
aligned to known peptide sequences in GeneBank and identifies
this gene unambiguously as the human homolog of the previously
described /3-subunits of the mouse (8) and bovine (7) cGMP PDE
gene. Moreover, analysis of the C-terminus of the peptide
between position 555 and 792 (Met =1 of the /3-subunit of the
Figure 4. Long range restriction map of loci D4S133 (probe 281), D4S228 (probe
PI.2), and D4S90 (probe D5). Probe PI.2 is isolated from an internal location
of the #-subunit of the cGMP PDE gene (fig 1) and, therefore, localizing the
gene approximately 700 kb proximal to the 4p telomere. The direction of
transcription of the gene relative to the 4p telomere is indicated by the arrow.
Restriction enzymes: NotI (N), Mlul (M), Nrul (Nr), and SacII (S). Brackets
denote partially methylated enzyme recognition sites. Numbers are given in kb.
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Figure 5. Correlation between genomic organization of exons 1 to 22 and the
three proposed domains (catalytic core, noncatalytic binding domain I and
noncatalytic binding domain II) (29, 30) in the primary amino acid sequence of
the photoreceptor cGMP PDEs. The proposed domain I is encoded by the three
most 5' exons which are physically separated from the other 19 exons by at least
17 kb of intronic sequences.
bovine cGMP PDE) reveals that over 85 % of the amino acid
residues are identical between the human a- and /3-subunit of
the cGMP PDEs. This supports earlier findings of a strong
conservation in this region in all members of the
phosphodiesterase family (5,31) which has led to the recognition
of this domain as having significant functional importance as the
catalytic core for cGMP hydrolysis (32, 33).
To our knowledge, this is the first report providing a thorough
analysis of the genomic organization of a cGMP PDE gene. Thus
far only cDNAs for the human a- and y- and the mouse and
bovine a-, /?-, and 7-subunits of the cGMP PDEs have been
described (4, 5, 7, 33, 34). We have now sequenced the complete
genomic locus encoding the proposed catalytic core, the putative
noncatalytic binding domain n, and the noncatalytic cGMP-
binding domain I (33, 34) (Fig 2, fig 5).
The analysis of the genomic organization of the gene reveals
some interesting features. The putative catalytic core and the
noncatalytic cGMP binding domain II are encoded by 19 exons
which are tightly clustered within 17 kb of DNA, whereas the
three most 5' exons are physically separated by a large intron
of at least 17 kb in size (fig 1, fig 5). In addition, this 17 kb
intron contains a strong CpG-rich island which is defined by one
SacII, one EagI, and two BssHTI sites within lkb of DNA and
which reveals a G+C content of over 80% (1). CpG-rich islands
have been frequently found to mark the 5' ends of genes (35).
Interestingly, the three physically separated 5' exons encode
the putative noncatalytic cGMP binding domain I (fig 5) which
can be regarded as a tandem repeat of the noncatalytic cGMP
binding domain II (33, 34). Tissues other than the retina might
not include the three most 5' exons by using an alternate
promotor. This alternate promotor could be represented by
sequences around CpG-rich island II (fig 1) and would be
expected to generate a modified transcript at least 700 bp smaller
than the retina homolog. It is interesting to note that the altered
size of the rare brain transcript could be explained by assuming
a differential transcriptional start site in brain tissue. Alternatively,
differential splicing of the primary transcript in brain could also
account for a smaller transcript. Isolation of full length retina
and brain cDNAs corresponding to this locus are currently under
way and are required to resolve this question (Collins et al, in
preparation).
Recently, evidence has been provided that the degenerative
process in the retinal degeneration (rd) mouse is caused by a
defect in the /3-subunit of the rod cGMP PDE (8). The rd mouse
is considered an animal model for autosomal recessive retinitis
pigmentosa (RP) as homozygous mice have been shown to display
hereditary progressive degeneration of retinal photoreceptors (36,
37). Retinal degeneration in these mice is preceded by elevated
levels of cGMP in the retina as a result of deficient cGMP PDE
activity (38, 39).
In human, RP is clinically and genetically heterogenous and
is a major cause of blindness with a prevalence ranging from
1/3000 to 1/7000 (40, 41). In the Caucasian population, RP is
inherited most frequently (84%) as an autosomal recessive trait
(42). However, even within this category of autosomal recessive
RP, a large number of clinically distinct retinopathies can be
defined including Usher syndrome, Leber's amaurosis and
Stargardt's disease. The cloning of the human homolog for the
mouse /3-subunit will now allow assessment as to whether any
form of human retinal degeneration corresponds to the previously
described mouse model. Moreover, the knowledge of the
genomic sequences of the exon/intron boundaries will facilitate
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rapid analysis of affected patients for DNA sequence alterations
without the need for retinal RNA.
The rd locus has been mapped in the mouse between the genes
for a-feto protein (Afp) and /3-glucuronidase (Gus) (43). This
region is well outside the conserved linkage group between mouse
chromosome 5 and human chromosome 4p which has been
established between markers D4S62h and Kit (44, 45). If the
location of the /3-subunit of the cGMP PDE can be definitely
mapped between Afp and Gus in the mouse, we would have to
assume more than one syntenic region for distal human 4p. A
chromosomal rearrangement in the mouse which interrupts a
syntenic group and places more distal markers from human 4p
to a more proximal position in the mouse would have to be
postulated.
The /3-subunit of the cGMP PDE maps to a previously
described candidate region for the Huntington Disease (HD) gene.
This gene, however, is predominantly expressed in human retina
and the absence of any obvious retinal changes in patients with
HD would appear to make it less likely that a defect in this gene
causes HD. However, alternate splicing or expression of a
defective gene with different tissue vulnerabilities could
theoretically result in tissue specific defects. Final confirmation
that this gene is not involved in HD awaits detailed sequence
analysis of affected HD patients and their comparison with normal
controls.
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